Condition
Methotrexate Adverse Reaction
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed3
Not Yet Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07094880Phase 4CompletedPrimary
Subcuteous Methotrexate in Rheumatoid Arthritis
NCT06641128Phase 4Not Yet Recruiting
The Possible Efficacy and Protective Effect of Empagliflozin in Rheumatoid Arthritis Patients Treated with Methotrexate
NCT04540250CompletedPrimary
Stratification of Oral Ulcers in Rheumatoid Arthritis Patients Kept on Methotrexate
NCT02591823Unknown
Hair Fall in Patients on Low Dose Methotrexate
NCT02011022Not ApplicableCompletedPrimary
Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies
Showing all 5 trials